GMP IPO Watch
DSP Nifty Healthcare ETF
DSP Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | +4.16% | +2.49% | 69 of 229 |
| 1M | +2.99% | +1.66% | 95 of 227 |
| 3M | -1.24% | -5.03% | 30 of 227 |
| 6M | +11.33% | -1.09% | 12 of 218 |
| YTD | +13.80% | -4.12% | 10 of 229 |
| 1Y | +12.05% | -2.00% | 16 of 193 |
| 2Y | +7.52% | +3.18% | 21 of 150 |
| INCEPTION | +15.10% | — | — |
Ranked among: Exchange Traded Funds (ETFs) - Other ETF.
Rolling Returns
| Period | Average | Best | Worst | Positive Periods | Consistency |
|---|---|---|---|---|---|
| 3M | +3.65% | +24.00% | -12.58% | 66% | 27% |
| 6M | +7.09% | +26.71% | -12.24% | 74% | 31% |
| 1Y | +9.33% | +23.82% | -4.60% | 94% | 40% |
| 2Y | +10.21% | +15.32% | +2.86% | 100% | 43% |
Rolling returns show the average, best and worst outcome an investor would have seen entering at any point in the window.
NAV History
AUM Trend (₹ Cr, quarterly average)
Expense Ratio Trend
Portfolio · Sep 2026
Asset Allocation
- Equity99.92%
- Debt0.00%
- Cash0.08%
- Other0.00%
Market Cap Split
- Large Cap47.77%
- Mid Cap48.35%
- Small Cap3.80%
- Others0.08%
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 39.39 | — |
| P/B | 5.49 | — |
| Price / Sales | 5.66 | — |
| Price / Cash Flow | 30.77 | — |
| Dividend Yield (%) | 0.62 | — |
Holdings · Sep 2026
| Holding | Sector | Weight | Change (1M) |
|---|---|---|---|
| Sun Pharmaceutical | Pharmaceuticals & Biotechnology | 16.99% | -1.08% |
| Divis Laboratories | Pharmaceuticals & Biotechnology | 10.43% | +0.09% |
| Apollo Hospitals | Equity | 7.42% | -0.45% |
| Laurus Labs | Pharmaceuticals & Biotechnology | 6.81% | +0.40% |
| Cipla | Pharmaceuticals & Biotechnology | 6.69% | -0.13% |
| Dr Reddys Laboratories | Pharmaceuticals & Biotechnology | 6.64% | +0.59% |
| Torrent Pharmaceuticals | Pharmaceuticals & Biotechnology | 6.24% | -0.15% |
| Max Healthcare Institute | Equity | 6.11% | -0.56% |
| Lupin | Pharmaceuticals & Biotechnology | 4.36% | -0.21% |
| Aurobindo Pharma | Pharmaceuticals & Biotechnology | 4.08% | -0.01% |
| Fortis Healthcare | Equity | 3.54% | -0.52% |
| Glenmark Pharmaceuticals | Pharmaceuticals & Biotechnology | 3.11% | -0.10% |
| Alkem Laboratories | Pharmaceuticals & Biotechnology | 2.75% | +0.07% |
| Zydus Life Science | Pharmaceuticals & Biotechnology | 2.54% | +0.04% |
| Mankind Pharma | Pharmaceuticals & Biotechnology | 2.51% | +0.16% |
View all 22 holdings
| IPCA Laboratories | Pharmaceuticals & Biotechnology | 2.36% | +0.00% |
| Biocon | Pharmaceuticals & Biotechnology | 2.28% | -0.25% |
| Gland Pharma | Pharmaceuticals & Biotechnology | 2.04% | — |
| Krishna Institute of Medical Sciences | Equity | 1.76% | — |
| Abbott | Pharmaceuticals & Biotechnology | 1.26% | +0.09% |
| TREPS / Reverse Repo Investments | Reverse Repo / TREPS | 0.10% | — |
| Net Receivables/Payables | Net Current Assets | -0.02% | — |
Sector Allocation · Sep 2026
Risk Metrics
Standard Deviation
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 14.02 | 16.68 | Low Volatility |
What is this?
Annualized population standard deviation of daily denomination-adjusted NAV returns, multiplied by sqrt(252). Values require a full timeframe of NAV history.
Sharpe Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.49 | -3.44 | Above Average |
| 3Y | 0.51 | -1.65 | Above Average |
What is this?
Annualized Sharpe ratio calculated from month-end NAV returns using the latest available FBIL Overnight MIBOR rate as the risk-free rate. For schemes with less than three years of history, the 3Y value uses since-inception data. Applied risk-free rate: 5.85% (published 2026-10-27).
Sortino Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 1.35 | -0.07 | Above Average |
What is this?
Annualized from daily NAV returns using a 0.00% minimum acceptable return; downside deviation includes only returns below this target.
Beta
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.95 | 0.96 | Good Risk Adjusted Returns |
What is this?
This value gives idea about how volatile fund performance has been compared to similar funds in the market. Lower beta implies the fund gives more predictable performance compared to similar funds in the market.
Tracking Difference
Versus Nifty Healthcare TRI, as of Sep 2026.
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
| Motilal Oswal Nasdaq Q50 ETF | +31.68% | +32.11% | — | +12.54% |
|
Nippon India Nifty Pharma ETF
Direct Plan
|
+21.73% | +22.78% | +14.98% | +13.27% |
| Motilal Oswal Nifty Capital Market ETF | +18.97% | — | — | +46.48% |
| Tata Silver Exchange Traded Fund | +18.13% | — | — | +36.90% |
|
SBI Silver ETF
Regular Plan · Growth
|
+17.82% | — | — | +31.22% |
| Edelweiss Silver ETF | +17.74% | — | — | +33.12% |
| Kotak Silver ETF | +17.70% | +34.19% | — | +26.36% |
| ICICI PRUDENTIAL SILVER ETF | +17.67% | +34.27% | — | +22.78% |
| Motilal Oswal Silver ETF | +17.57% | — | — | +40.42% |
|
Nippon India Silver ETF
Direct Plan
|
+17.45% | +33.95% | — | +23.75% |
More From DSP Asset Managers Private Limited
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
DSP World Mining Overseas Equity Omni FoF
Direct Plan · Growth
|
+31.62% | +27.66% | +17.65% | +8.28% |
|
DSP World Gold Mining Overseas Equity Omni FoF
Direct Plan · IDCW
|
+23.58% | +45.13% | +20.64% | +6.10% |
|
DSP US Specific Equity Omni FoF
Direct Plan · Growth
|
+22.12% | +28.17% | +17.73% | +17.61% |
| DSP Silver ETF | +17.25% | +34.02% | — | +29.88% |
|
DSP Silver ETF Fund of Fund
Direct Plan · IDCW
|
+16.31% | — | — | +49.42% |
|
DSP Global Clean Energy Overseas Equity Omni FoF
Direct Plan · Growth
|
+15.30% | +20.08% | +8.27% | +6.67% |
|
DSP Healthcare Fund
Direct Plan · Growth
|
+15.27% | +21.39% | +16.01% | +22.53% |
| DSP Gold ETF | +13.34% | +29.74% | — | +25.38% |
|
DSP Gold ETF Fund of Fund
Direct Plan · IDCW
|
+12.67% | — | — | +29.72% |
|
DSP Nifty Healthcare Index Fund
Direct Plan · Growth
|
+12.03% | — | — | +12.80% |
About This Scheme
Investment Objective
The Scheme seeks to provide returns that, before expenses, correspond to the total return of the underlying index (Nifty Healthcare TRI), subject to tracking errors. There is no assurance that the investment objective of the Scheme will be achieved.
Stated Asset Allocation
A. Equity and Equity Related Securities of companies constituting Nifty Healthcare Index, the Underlying Index : 95% - 100%. B. Cash and Cash Equivalents : 0% - 5% For detailed asset allocation pattern, please refer to the Scheme Information Document
Exit Load
Nil
Fund Managers
Mr. Anil Ghelani, Mr. Diipesh Shah , Ms. Neha Rathi
Mr. Anil Ghelani - Primary, Mr. Diipesh Shah - Comanage, Ms. Neha Rathi - Comanage
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.